Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

READY TO PLAY GUINEA PIG AGAIN? PFIZER GETS OK FOR COVID “BIVALENT” JAB

It’s being called a “sharpened tool.”

Pfizer announced in a 22 August press release that they have applied for Emergency Use Authorization (EUA) approval of a “bivalent” COVID vaccine.

Sound familiar?

According to the press release:

“The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein, which is present in the original Pfizer-BioNTech COVID-19 Vaccine, together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. Pre-clinical data showed a booster dose of Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5-adapted bivalent vaccine in individuals 12 years of age and older is expected to start this month.”

The statement said that the submission to the U.S. Food and Drug Administration (FDA) regards a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

A July 2022 Nature magazine article detailed the difficulties of trying to produce effective vaccines for the COVID virus, characterizing the process as “shifting sands.”

The article noted that some scientists believe it is likely that entirely new variants will emerge that are far removed from similarity to current  SARS-CoV-2 strains, making vaccines potentially of little use.

“My concern is that there’s this huge focus on Omicron, and the assumption that Omicron is what we will be dealing with in the future,” virologist Penny Moore of the University of the Witwatersrand in Johannesburg, South Africa, was quoted in the article. “We have a strong track record of getting that wrong.” 

Reports of Injuries From Previous mRNA and DNA COVID Experimental Therapies Growing

Big Pharmaceuticals have profiteered from plying governments to push their vaccines, despite mounting evidence that their experimental and controversial technologies are harming people at greater rates than previously acceptable for traditional vaccines.

The Trends Journal has covered issues surrounding COVID gene level technologies and pharmaceutical company outsized profits in many articles. Samples include: